Research programme: psychiatric disorder therapeutics - Pierre Fabre

Drug Profile

Research programme: psychiatric disorder therapeutics - Pierre Fabre

Alternative Names: 94517; F 15063; F 15441; F 16615; F 94517

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pierre Fabre
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder; Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in France
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in France (PO)
  • 19 Nov 2008 Preclinical pharmacodynamics data on F 16615 and F 15063 presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top